# Centese

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/centese

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.centese.com
- Total disclosed funding: $2M
- Latest round: Series A (Aug 26, 2019)
- Investors on record: 1

## About

Centese, Inc. is a medical technology company that specializes in innovative surgical drainage solutions designed to enhance postoperative patient care, particularly in cardiac and thoracic surgery.Founded in 2015 and headquartered in the United States, Centese, Inc. focuses on developing advanced medical devices. The company has successfully completed 3 funding deals with the most recent being a Series A round in August 2019, where it raised USD 2.00 mn from Invest Nebraska Corporation. Evan Luxon serves as both the founder and CEO of the company, leading its vision and strategic direction. The total amount raised to date is USD 15.102 mn.Centese, Inc. specializes in surgical drainage solutions, primarily through its flagship product, Thoraguard. Thoraguard is designed for use in cardiac and thoracic surgery, providing effective drainage for patients recovering from various surgical procedures. The product has been cleared by the U.S. Food and Drug Administration (FDA) and is available for commercial sale, adhering to federal regulations that restrict its distribution to orders made by licensed physicians. The company targets hospitals and surgical centers, serving a diverse client base that includes healthcare providers and surgical practitioners across the United States, particularly in the cardiology and thoracic surgery sectors. By focusing on innovative surgical drainage solutions, Centese aims to enhance patient outcomes and streamline postoperative care.Centese, Inc. generates revenue primarily through direct sales of its medical device products, specifically Thoraguard. The company operates on a business-to-business (B2B) model, selling directly to healthcare facilities that require advanced surgical drainage solutions. The transaction structure typically involves hospitals and surgical centers placing orders for Thoraguard, which are fulfilled based on physician directives, ensuring compliance with relevant medical regulations. Revenue is largely driven by the volume of products ordered, reflecting the demand for safe and effective surgical drainage in postoperative care. As a recognized player in the surgical device market, Centese has positioned itself to capitalize on the growing need for innovative medical products in surgical settings.In August 2019, Centese, Inc. raised USD 2.00 mn in Series A funding, which will be utilized to support its strategic initiatives. The company is focusing on expanding its product line with new surgical drainage solutions and aims to enter additional markets within the United States over the next few years. Specific details regarding new product launches or targeted regions for expansion have not been disclosed, but the funding is expected to enhance research and development efforts.

## Funding rounds

- Series A, Aug 26, 2019, $2M — Invest Nebraska

## Investors

- Invest Nebraska (https://capitalatlas.ai/funds/invest-nebraska) — Series A